Filtered By:
Education: Learning
Management: Hospitals
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 273 results found since Jan 2013.
Based on voxel-based morphological analysis to investigate the effect of acupuncture-rehabilitation therapy on hippocampal volume and its neuroprotective mechanism in patients with vascular cognitive impairment with type 2 diabetes mellitus: A study protocol
Discussion:
This trial can clarify the effect of acupuncture-rehabilitation therapy on hippocampal volume and its intervention mechanism on oxidative stress injury in VCI patients with T2DM, and clarify the scientific connotation of its neuroprotective mechanism in the VCI patients with T2DM, in order to provide a theoretical basis for the clinical application of acupuncture-rehabilitation therapy in the treatment of VCI.
Trial registration:
Chinese Clinical Trial Registry (ChiCTR), ChiCTR2100047803. Registered 26 June, https://www.chictr.org.cn/showproj.aspx?proj=128707
Source: Medicine - December 23, 2021 Category: Internal Medicine Tags: Research Article: Study Protocol Clinical Trial Source Type: research
FDA Approves Two New Indications for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for XARELTO® (rivaroxaban): the treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients from birth to less than 18 years after at least five days of initial parenteral (injected or intravenous) anticoagulant treatment; and thromboprophylaxis (prevention of blood clots and blood-clot related events) in children aged two years and older with congenital heart disease who have...
Source: Johnson and Johnson - December 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Real-time reviews of research findings will help policymakers address global crises such as COVID-19
Real-time reviews of research findings could help policymakers address global crises such as COVID-19, saysthis articlepublished inNature. Living evidence was first developed by Cochrane and an important recommendation for future health emergencies that came out of the recent Cochrane Convenes meetings. According to scientists writing in the peer-reviewed journal Nature, policy missteps will continue to overshadow the global response to COVID-19 because policymakers are overwhelmed with rapidly shifting research evidence. Faced with new challenges such as the Omicron variant, decision-makers can ’t keep up wi...
Source: Cochrane News and Events - December 15, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news
Sensors, Vol. 21, Pages 7784: Detection of Unilateral Arm Paresis after Stroke by Wearable Accelerometers and Machine Learning
alle Åström
Recent advances in stroke treatment have provided effective tools to successfully treat ischemic stroke, but still a majority of patients are not treated due to late arrival to hospital. With modern stroke treatment, earlier arrival would greatly improve the overall treatment results. This prospective study was performed to asses the capability of bilateral accelerometers worn in bracelets 24/7 to detect unilateral arm paralysis, a hallmark symptom of stroke, early enough to receive treatment. Classical machine learning algorithms as well as state-of-the-art deep neural networks were evaluated on detectio...
Source: Sensors - November 23, 2021 Category: Biotechnology Authors: Johan Wasselius Eric Lyckeg ård Finn Emma Persson Petter Ericson Christina Brog årdh Arne G. Lindgren Teresa Ullberg Kalle Åström Tags: Article Source Type: research
Janssen to Present the Strength and Promise of its Hematologic Malignancies Portfolio and Pipeline at ASH 2021
RARITAN, N.J., November 4, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than 45 company-sponsored abstracts, including 11 oral presentations, plus more than 35 investigator-initiated studies will be featured at the American Society of Hematology (ASH) Annual Meeting and Exposition. ASH is taking place at the Georgia World Congress Center in Atlanta and virtually from December 11-14, 2021.“We are committed to advancing the science and treatment of hematologic malignancies and look forward to presenting the latest research from our robust portfolio and pipeline during ASH...
Source: Johnson and Johnson - November 5, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Bringing WISDOM to Breast Cancer Care
Dr. Laura Esserman answers the door of her bright yellow Victorian home in San Francisco’s Ashbury neighborhood with a phone at her ear. She’s wrapping up one of several meetings that day with her research team at University of California, San Francisco, where she heads the Carol Franc Buck Breast Care Center. She motions me in and reseats herself at a makeshift home office desk in her living room, sandwiched between a grand piano and set of enormous windows overlooking her front yard’s flower garden. It’s her remote base of operations when she’s not seeing patients or operating at the hospita...
Source: TIME: Health - October 22, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized Source Type: news
Concussions and kids: Project co-led by UCLA gets $10 million grant from NIH
A research project co-led by theUCLA Steve Tisch BrainSPORT Programaimed at improving the assessment and treatment of concussions in school-aged children has been awarded $10 million by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health.The grant to the Four Corners Youth Consortium, agroup of academic medical centers studying pediatric concussions, will supportConcussion Assessment, Research and Education for Kids, or CARE4Kids, a multisite study that will enroll more than 1,300 children and teens nationwide, including an estimated 240 in Southern California.CARE4Kids re...
Source: UCLA Newsroom: Health Sciences - October 7, 2021 Category: Universities & Medical Training Source Type: news
New Phase 3 Data Suggest Positive Effect and Show Similar Safety with XARELTO ® (rivaroxaban) Compared to Aspirin in Pediatric Fontan Procedure Patients at Risk for Blood Clots and Blood Clot-Related Events
RARITAN, NJ, September 27, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today new data from the Phase 3 UNIVERSE study showing treatment with XARELTO® (rivaroxaban) in an oral suspension formulation, compared to treatment with aspirin, was associated with numerically fewer blood clots and clinical events strongly associated with blood clots in pediatric patients (aged 2-8 years) who have undergone the Fontan procedure. [1] These findings, which were published this month in the Journal of the American Heart Association and included in a recent New Drug Application submitted to the U.S. F...
Source: Johnson and Johnson - September 27, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Pediatric COVID-19 Cases Are Surging, Pushing Hospitals —and Health Care Workers—to Their Breaking Points
Aug. 20 was a good day in the pediatric intensive care unit at Children’s Hospital New Orleans. Carvase Perrilloux, a two-month-old baby who’d come in about a week earlier with respiratory syncytial virus and COVID-19, was finally ready to breathe without the ventilator keeping his tiny body alive. “You did it!” nurses in PPE cooed as they removed the tube from his airway and he took his first solo gasp, bare toes kicking.
Downstairs, Quintetta Edwards was preparing for her 17-year-old son, Nelson Alexis III, to be discharged after spending more than two weeks in the hospital with COVID-19—fir...
Source: TIME: Health - August 26, 2021 Category: Consumer Health News Authors: Jamie Ducharme/New Orleans, La. Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
FDA Approves Expanded Peripheral Artery Disease (PAD) Indication for XARELTO ® (rivaroxaban) Plus Aspirin to Include Patients After Lower-Extremity Revascularization (LER) Due to Symptomatic PAD
RARITAN, N.J., August 24, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded peripheral artery disease (PAD) indication for the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) to include patients following recent lower-extremity revascularization (LER) due to symptomatic PAD. The approval is based on data from the Phase 3 VOYAGER PAD study. With this approval, XARELTO® is the first and only therapy indicated to help reduce the risks of major cardiovascular (CV) events in p...
Source: Johnson and Johnson - August 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Sensors, Vol. 21, Pages 5334: Prediction of Myoelectric Biomarkers in Post-Stroke Gait
This study aimed to evaluate the potential myoelectric biomarkers for the classification of stroke-impaired muscular activity of the stroke patient group and the muscular activity of the control healthy adult group. We also proposed an EMG-based gait monitoring system consisting of a portable EMG device, cloud-based data processing, data analytics, and a health advisor service. This system was investigated with 48 stroke patients (mean age 70.6 years, 65% male) admitted into the emergency unit of a hospital and 75 healthy elderly volunteers (mean age 76.3 years, 32% male). EMG was recorded during walking using the portable...
Source: Sensors - August 7, 2021 Category: Biotechnology Authors: Iqram Hussain Se-Jin Park Tags: Article Source Type: research
Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with congenita...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Exoskeleton-assisted Anthropomorphic Movement Training (EAMT) for Post-stroke Upper Limb Rehabilitation: A Pilot Randomized Controlled Trial
Stroke is the leading cause of mortality and disability worldwide, and it places a substantial burden on healthcare services and the socioeconomic system.1 More than two-thirds of individuals with stroke have upper extremity motor impairment and functional deficits at hospital admission,2, 3 manifesting as muscle weakness, loss of coordination and abnormal synergies.4 Moreover, upper limb dysfunction leads to long-term limitations in activities of daily living (ADL) and social participation.5 Extensive studies have reported that participants can benefit from high-intensity, task-specific training programs based on motor-le...
Source: Archives of Physical Medicine and Rehabilitation - June 23, 2021 Category: Rehabilitation Authors: Ze-Jian Chen, Chang He, Feng Guo, Cai-Hua Xiong, Xiao-Lin Huang Tags: Original Research Source Type: research
